Hematologic Malignancy
T Lymphoblastic Leukemia/Lymphoma
CI-CAN-00001560Explore in graph →
Hematologic57 active trials8 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001560Explore in graph →
Clinical trials
140 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06633354 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06598722 | BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. | recruiting | Phase 2 | 206 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | recruiting | Phase 1 | 9 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05620680 | CD7 CAR-T Cells in T-cell Lymphoma/Leukemia | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Nov 12, 2024source: clinicaltrials